Investing in the biotech industry can be a risky business. In most instances, the deck is stacked against a company succeeding. The vast majority of preclinical studies will fail to reach human trials, and there’s no guarantee that a compound in clinical trials will reach pharmacy shelves. Not surprisingly, about 9 in 10 biotech stocks are currently losing money, and some simply may not survive.